Spondyloarthritis & psoriatic arthritis
The serum level of sclerostin decreases in radiographic axial spondyloarthritis patients with fatty lesions
Authors' conclusion
In the r-axSpA patients with fatty lesions, serum sclerostin levels are declined.
Study context
- Population
- Patients with radiographic axial spondyloarthritis (r-axSpA)
- Participants
- 73 patients
- Exposure
- r-axSpA with fatty lesions vs r-axSpA without fatty lesions
- Fatty lesionsn = 48
- Without fatty lesionsn = 25reference
- Outcome
- Serum bone turnover markers (sclerostin, OPG, PINP, CTX-I, OC) by fatty lesion status
Methodological detailsELISA-measured bone turnover markers, univariate and multivariate correlation analysis
- ELISA-measured bone turnover markers
- Univariate and multivariate correlation analysis
Main finding
As reported in the abstract
Serum sclerostin
- Serum sclerostin significantly lower in r-axSpA with fatty lesions than without
- No significant differences in osteoprotegerin (OPG), PINP, CTX-I or osteocalcin (OC) between groups
- Fatty lesions vs Without fatty lesions: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| mSASSSHigher with fatty lesions | P < 0.001 |
Correlation with CBM scores (univariate)
- Body mass index (BMI), ρ
- 0.311
- Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), ρ
- 0.306
- Sclerostin, ρ
- −0.920
Correlation of sclerostin with CBM scores (multivariate)
- Sclerostin, ρ
- −0.040
- P
- P < 0.001
- Only sclerostin correlated in multivariate analysis
Original publication
The serum level of sclerostin decreases in radiographic axial spondyloarthritis patients with fatty lesions. Arthritis Res Ther. Published 16 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →